Dafna Capital Management LLC Ascendis Pharma A/S Transaction History

Dafna Capital Management LLC

$331 Million
Q1 2025

A detailed history of Dafna Capital Management LLC transactions in Ascendis Pharma A/S stock. As of the latest transaction made, Dafna Capital Management LLC holds 80,398 shares of ASND stock, worth $14.1 Million. This represents 3.78% of its overall portfolio holdings.

Number of Shares

80,398

Previous 103,355 22.21%

Holding current value

$14.1 Million

Previous $14.2 Million 11.93%

% of portfolio

3.78%

Previous 3.87%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 15, 2025	SELL	$119.49 - $168.84 $2.74 Million - $3.88 Million	-22,957 Reduced 22.21%	80,398 $12.5 Million
Q4 2024 Feb 14, 2025	BUY	$122.0 - $146.6 $1.68 Million - $2.02 Million	13,783 Added 15.39%	103,355 $14.2 Million
Q3 2024 Nov 14, 2024	BUY	$113.0 - $153.43 $971,800 - $1.32 Million	8,600 Added 10.62%	89,572 $13.4 Million
Q2 2024 Aug 14, 2024	SELL	$121.07 - $153.67 $1.39 Million - $1.77 Million	-11,500 Reduced 12.44%	80,972 $11 Million
Q1 2024 May 15, 2024	SELL	$123.45 - $159.4 $3.83 Million - $4.94 Million	-31,000 Reduced 25.11%	92,472 $14 Million
Q4 2023 Feb 14, 2024	SELL	$86.1 - $127.36 $1.1 Million - $1.62 Million	-12,740 Reduced 9.35%	123,472 $15.6 Million
Q3 2023 Nov 14, 2023	BUY	$86.5 - $103.97 $86,500 - $103,970	1,000 Added 0.74%	136,212 $12.8 Million
Q1 2023 May 15, 2023	BUY	$104.9 - $126.78 $524,500 - $633,900	5,000 Added 3.84%	135,212 $14.5 Million
Q4 2022 Feb 14, 2023	SELL	$99.42 - $131.97 $546,810 - $725,835	-5,500 Reduced 4.05%	130,212 $15.9 Million
Q3 2022 Nov 14, 2022	SELL	$84.03 - $110.23 $294,105 - $385,805	-3,500 Reduced 2.51%	135,712 $14 Million
Q2 2022 Aug 15, 2022	BUY	$78.08 - $117.61 $8.48 Million - $12.8 Million	108,600 Added 354.76%	139,212 $12.9 Million
Q1 2022 May 16, 2022	BUY	$102.18 - $135.75 $2 Million - $2.66 Million	19,612 Added 178.29%	30,612 $3.59 Million
Q4 2021 Feb 14, 2022	BUY	$127.1 - $169.66 $1.4 Million - $1.87 Million	11,000 New	11,000 $1.48 Million
Q3 2021 Nov 15, 2021	SELL	$112.67 - $176.92 $804,125 - $1.26 Million	-7,137 Closed	0 $0
Q2 2021 Aug 16, 2021	SELL	$121.62 - $145.29 $1.96 Million - $2.34 Million	-16,100 Reduced 69.29%	7,137 $939,000
Q4 2020 Feb 16, 2021	SELL	$151.2 - $182.76 $907,199 - $1.1 Million	-6,000 Reduced 20.52%	23,237 $3.88 Million
Q3 2020 Nov 16, 2020	BUY	$134.29 - $154.32 $2.01 Million - $2.31 Million	15,000 Added 105.36%	29,237 $4.51 Million
Q2 2020 Aug 14, 2020	SELL	$110.87 - $156.01 $2.16 Million - $3.04 Million	-19,500 Reduced 57.8%	14,237 $2.11 Million
Q1 2020 May 15, 2020	BUY	$97.01 - $145.11 $546,845 - $817,985	5,637 Added 20.06%	33,737 $3.8 Million
Q4 2019 Feb 14, 2020	SELL	$91.45 - $139.12 $2.96 Million - $4.5 Million	-32,380 Reduced 53.54%	28,100 $3.91 Million
Q3 2019 Nov 14, 2019	BUY	$95.8 - $118.9 $105,380 - $130,790	1,100 Added 1.85%	60,480 $5.83 Million
Q2 2019 Aug 14, 2019	BUY	$107.11 - $132.09 $1.61 Million - $1.98 Million	15,000 Added 33.8%	59,380 $6.84 Million
Q1 2019 May 15, 2019	SELL	$62.15 - $129.99 $2.04 Million - $4.27 Million	-32,862 Reduced 42.54%	44,380 $5.22 Million
Q3 2018 Nov 14, 2018	BUY	$63.77 - $76.28 $223,003 - $266,751	3,497 Added 4.74%	77,242 $5.47 Million
Q2 2018 Aug 13, 2018	SELL	$58.55 - $73.92 $322,025 - $406,560	-5,500 Reduced 6.94%	73,745 $4.91 Million
Q1 2018 May 15, 2018	SELL	$38.98 - $68.04 $1.77 Million - $3.09 Million	-45,394 Reduced 36.42%	79,245 $5.18 Million
Q4 2017 Feb 14, 2018	BUY	$31.98 - $40.38 $1.68 Million - $2.12 Million	52,413 Added 72.57%	124,639 $4.99 Million
Q3 2017 Nov 14, 2017	BUY	$26.89 - $37.1 $1.94 Million - $2.68 Million	72,226	72,226 $2.62 Million

Others Institutions Holding ASND

# of Institutions

270

Shares Held

61.9M

Call Options Held

151K

Put Options Held

226K

View Full List

About Ascendis Pharma A/S

Ticker ASND
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,810,200
Market Cap $9.81B
Description
Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult h...

More about ASND

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Dafna Capital Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Dafna Capital Management LLC with notifications on news.

Account

Dafna Capital Management LLC Ascendis Pharma A/S Transaction History